Industry Involvement

Sunday 28 October

14.30–16.00  Framing the ART: Drawing on a Generation of Innovation
Please click here to view the programme
This promotional meeting is organised and fully funded by Gilead Sciences Europe Ltd.

Monday 29 October

17.30–19.00 HIV advances – evolving to improve wellbeing
Please click here to view the programme.
Medical education event supported by Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA

Tuesday 30 October

08.30–10.00 Keeping Ahead of the Curve: Looking Across the Patient Spectrum
Please click here to view the programme.
Symposium Sponsored by Merck Sharp & Dohme

17.30–19.00 Treatment Paradigms: Fewer Drugs, More Questions?
Please click here to view the programme.
Scientific Exchange Symposium organised by Viiv Healthcare

Logo Gilead
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information, visit

Logo Janssen
About Janssen Pharmaceutical Companies
At Janssen Pharmaceutical Companies of Johnson & Johnson we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it.

Stopping HIV takes relentless focus, breakthrough innovation and global collaboration. Janssen stands united with the global community to make an HIV-free world a reality. Building on our 25-year legacy of commitment to end HIV, our goal is to help ensure that every baby is born HIV-free, adolescents and adults stay HIV-free and people living with HIV have access to the medicines they need. Furthermore, we are working with partners around the world to advance R&D of several innovative preventive methods, including an HIV vaccine, which remains a top global health priority.

By utilising our resources and expertise, together we can #makeHIVhistory. Learn more at

Our Commitment to HIV
For more than 30 years, Merck has been committed to scientific research and discovery in HIV and we continue to be driven by the conviction that more medical advances are still to come. Our focus is on pursuing research that addresses unmet medical needs and helps people living with HIV and their communities. We are making choices, including in our HIV pipeline, that could potentially change the HIV treatment and prevention paradigms, and help bring us closer to the goal of finding a cure. We remain committed to working hand-in-hand with our partners in the global HIV community to address the complex challenges to continued progress. For more information, visit

ViiV Logo - high res 2
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined as a shareholder in October 2012. The company’s aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.
For more information on the company, its management, portfolio, pipeline, and commitment, please visit